Ingenious Synergy of a Pathology‐Specific Biomimetic Multifunctional Nanoplatform for Targeted Therapy in Rheumatoid Arthritis
Small · 2024
DOI: 10.1002/smll.202305197 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2024. Verfasst von Hong Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery and Orthopedic Research Institution, West China Hospital, Sichuan University, Chengdu, 610041, China. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Arthritis, Experimental. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Based on the pathological characteristics of rheumatoid arthritis, including the overproduction of reactive oxygen species (ROS), inflammatory responses, and osteoclast differentiation, a biomimetic multifunctional nanomedicine (M‐M@I) is designed. Iguratimod (IGU) is loaded, which inhibits inflammatory responses and osteoclast differentiation, into mesoporous polydopamine (MPDA), which scavenges ROS. Subsequently, the nanoparticles are coated with a cell membrane of macrophages to achieve actively targeted delivery of the nanoparticles to inflamed joints. It is shown that the M‐M@I nanoparticles are taken up well by lipopolysaccharide‐induced RAW 264.7 macrophages or bone marrow‐derived macrophages (BMDMs). In vitro, the M‐M@I nanoparticles effectively scavenge ROS, downregulate genes related to inflammation promotion and osteoclast differentiation, and reduce the proinflammatory cytokines and osteoclast‐related enzymes. They also reduce the polarization of macrophages to a pro‐inflammatory M1 phenotype and inhibit differentiation into osteoclasts. In mice with collagen‐induced arthritis, the M‐M@I nanoparticles accumulate at arthritic sites and circulate longer, significantly mitigating arthritis symptoms and bone destruction. These results suggest that the pathology‐specific biomimetic multifunctional nanoparticles are effective against rheumatoid arthritis, and they validate the approach of developing multifunctional therapies that target various pathological processes simultaneously.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery and Orthopedic Research Institution, West China Hospital, Sichuan University, Chengdu, 610041, China.
- College of Polymer Science and Engineering, State Key Laboratory of Polymer Materials Engineering, Sichuan University, Chengdu, 610065, China.
- Department of Ultrasound, West China Hospital, Sichuan University, Chengdu, 610041, China.
- State Key Laboratory of Oral Diseases, West China Hospital of Stomatology, Med-X Center for Materials, Sichuan University, Chengdu, 610041, China.
ORCID-Profile: Hong Xu, Duan Wang, Jinwei Xie, Zeyu Huang, Weinan Zeng, Xiaoxue Fu, Zongke Zhou
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Xu, H., Wang, Y., Rong, X., Wang, D., Xie, J., Huang, Z., Zeng, W., Fu, X., Li, J., & Zhou, Z. (2024). Ingenious Synergy of a Pathology‐Specific Biomimetic Multifunctional Nanoplatform for Targeted Therapy in Rheumatoid Arthritis. Small. https://doi.org/10.1002/smll.202305197
Vancouver
Xu H, Wang Y, Rong X, Wang D, Xie J, Huang Z, et al. Ingenious Synergy of a Pathology‐Specific Biomimetic Multifunctional Nanoplatform for Targeted Therapy in Rheumatoid Arthritis. Small. 2024. doi:10.1002/smll.202305197
BibTeX
@article{Xu2024,
author = {Xu, Hong and Wang, Yuemin and Rong, Xiao and Wang, Duan and Xie, Jinwei and Huang, Zeyu and Zeng, Weinan and Fu, Xiaoxue and Li, Jianshu and Zhou, Zongke},
title = {Ingenious Synergy of a Pathology‐Specific Biomimetic Multifunctional Nanoplatform for Targeted Therapy in Rheumatoid Arthritis},
journal = {Small},
year = {2024},
doi = {10.1002/smll.202305197}
}
EUVIMED